Agency IQ

APRIL 8, 2024

Since these issues could occur during the investigational phase of clinical development as well as in the post-marketing setting—and product status could very well differ by country/region—ICH members determined that these guidelines should be developed to facilitate the exchange of information in both settings.

FDA 40

FDA Production Regulations Vaccine 40

Agency IQ

JUNE 17, 2024

On the other hand, ChemRRV encompasses restrictions taken from REACH Annex XVII (the list of restrictions on the use, placing on the market, and manufacturing of substances), as well as REACH Annex XIV, the list of substances flagged for phase-out from the market, except when specific use authorizations are secured (i.e.,

Regulations 40

Regulations Production International Packaging 40

Agency IQ

MAY 17, 2024

BY RACHEL COE, MSC | MAY 10, 2024 5:19 PM CDT Generic Drug User Fee Amendments (GDUFA) III The Generic Drug User Fee Agreement (GDUFA) was first passed in 2012 as part of the FDA Safety and Innovation Act (FDASIA) to bolster FDA’s resources for the review and approval of generic drugs. What to expect on the day of the meeting?

Science 40

Science FDA Drugs Production 40

Agency IQ

AUGUST 2, 2024

Have your say” feedback periods are winding down in August, including one updating the lists of hazardous substances regulated under Regulation (EU) 649/2012, which implements the Rotterdam Convention on the prior informed consent (PIC) procedure. food packaging, kitchen and tableware and food processing equipment).

Regulations 40

Regulations Production Packaging International 40

Agency IQ

JUNE 16, 2023

0910-AI84 December 2023 Final Rule Stage Fixed-Combination and Co-Packaged Drugs: Applications for Approval and Combinations of Active Ingredients Under Consideration for Inclusion in an Over-the-Counter Monograph The final rule amends FDA regulations on fixed-combination prescription and nonprescription drugs.

Regulations 40

Regulations FDA Science Production 40

Agency IQ

NOVEMBER 27, 2023

In some cases, the groups requested ad-by-ad reviews, potentially via collaboration with independent market research organizations. The results of this study were posted to the docket for the proposed rule in February 2012. submitted the results of their own market research study on a fictitious drug.

FDA 40

FDA Science Drugs Regulations 40

Agency IQ

OCTOBER 27, 2023

December 2023 Fixed-Combination and Co-Packaged Drugs: Applications for Approval and Combinations of Active Ingredients Under Consideration for Inclusion in an Over-the-Counter Monograph (Final Rule) The final rule amends FDA regulations on fixed-combination prescription and nonprescription drugs.

FDA 40

FDA Science Regulations Production 40

The Pharma Data

MAY 14, 2021

After having emergency surgery in 2012, I lost 10 pounds which got me down to my pre pregnancy weight, but I was not fit and strong, I was tired. She inspires clients to change their physique and their minds more than any diet, or weight loss plan on the market. Everyday, Dawn brings motivation and passion to her gym.

Production 52

Production Vaccine Packaging Doctors 52

Agency IQ

JUNE 7, 2024

The regulations increase focus on post-market requirements and expect continuous and instantaneous updates to all reports and documents when either the product or the benefit-risk ratio changes. These comprise the MDS series (MDS 7000, 7200). See Table 4 for a list of the codes that have the highest Notified Body designations.

Regulations 40

Regulations Compliance Packaging Production 40

The Pharma Data

AUGUST 3, 2021

Selling, General & Administrative (SG&A) expenses increased 7% driven by marketed product support due to increased customer engagement in response to the pandemic recovery and investment in new product launches. Tax Court to contest notices of deficiencies received from the IRS during the quarter for 2010, 2011 and 2012.

Biosimilars 52

Biosimilars Production Treatment FDA 52

Agency IQ

AUGUST 4, 2023

This past week, the MHRA provided guidance on labeling of medicines destined for Northern Ireland, with provisions to ensure that medicines only move into Northern Ireland market and don’t re-enter E.U. The European centralized marketing authorization procedure is no longer a valid medicines approval pathway for the U.K. member states.

Packaging 40

Packaging Licensing Licensing Regulations 40

Agency IQ

SEPTEMBER 22, 2023

It appears the issue is largely the result of unclear labeling for biocidal disinfectants, an aspect French regulators may flag in future market authorization evaluations for these products. Market authorization for a biocidal disinfectant product can be applied for at the national or EU-wide level.

Regulations 40

Regulations Production Packaging Marketing 40

Agency IQ

MAY 31, 2024

Even small changes in the Parliament’s composition could have an impact on ongoing legislative discussions, such as the revisions to the pharma reform package. The current European Parliament and Commission have confirmed their position on the pharma package, but the European Council is still working on its negotiation position.

Regulations 40

Regulations Production Compliance Pharmaceuticals 40

Agency IQ

MAY 3, 2024

The pharma reform package remains in E.U. In the interim, the European Council will continue to discuss the package, and stakeholders may gain some insight into the Council’s thinking near the end of May. leaders’ eyesight as the Parliament winds down ahead of its June elections. On April 10, the E.U. On April 10, the E.U.

Regulations 40

Regulations Clinical Trials Production Biosimilars 40

Agency IQ

AUGUST 2, 2024

Another legislative area that will also likely receive more attention will be the pharma reform package , since the two Parliament rapporteurs to lead the package negotiations were recently appointed.

Regulations 40

Regulations Clinical Trials Production Trials 40

Agency IQ

OCTOBER 20, 2023

PFAS are used to repel water, oil, stains, and increase durability, and are found in a wide array of consumer and industrial products including non-stick cookware, fabric treatments, food packaging, cleaners, textiles, leather, cosmetics, paper and paints, fire-fighting foams (AFFF), and wire insulation.

Regulations 40

Regulations Production Packaging Treatment 40

Agency IQ

DECEMBER 1, 2023

December 2023 Fixed-Combination and Co-Packaged Drugs: Applications for Approval and Combinations of Active Ingredients Under Consideration for Inclusion in an Over-the-Counter Monograph (Final Rule) The final rule amends FDA regulations on fixed-combination prescription and nonprescription drugs.

FDA 40

FDA Science Regulations Production 40

Agency IQ

MARCH 29, 2024

The EPA is also proposing our response to a petition regarding the continued validity of EPA’s 2012 determination (and September 2017 affirmation) that participation in the Cross State Air Pollution Rule (CSAPR) meets the Regional Haze Rule’s criteria for an alternative to the application of source-specific BART.

Regulations 40

Regulations Compliance Production Government 40

Agency IQ

DECEMBER 15, 2023

For this routine MUR, EPA will only consider new methods or method revisions for which a complete, acceptable method package has been received by January 7, 2022. This routine Methods Update Rule (rMUR) was proposed in February 2023. EPA is not considering methods for new analytes in this routine MUR.

Regulations 40

Regulations Compliance Production Government 40

Agency IQ

OCTOBER 27, 2023

2050-AH28 National Emissions Standards for Hazardous Air Pollutants From Secondary Lead Smelting Proposed Rule Stage The Risk and Technology Review (RTR) for the Secondary Lead Smelters NESHAP (Subpart X) was promulgated on January 5, 2012 (77 FR 555). The Agency is now reconsidering that action. 2070-AL08 San Joaquin Valley PM2.5

Regulations 40

Regulations Compliance Science Production 40

Agency IQ

JUNE 16, 2023

The EPA is also proposing our response to a petition regarding the continued validity of EPA’s 2012 determination (and September 2017 affirmation) that participation in the Cross State Air Pollution Rule (CSAPR) meets the Regional Haze Rule’s criteria for an alternative to the application of source-specific BART.

Regulations 40

Regulations Compliance Production Science 40

Agency IQ

JULY 28, 2023

On March 27, the FDA finalized a transition guidance document covering products that had been marketed under enforcement discretion policies during the PHE. First, by March 2021, manufacturers were expected to conclude a risk assessment of their approved or marketed products to assess the risk of nitrosamines.

FDA 40

FDA Science Biosimilars Regulations 40

Codon

FEBRUARY 2, 2025

While air conditioning has some immediate, obvious health benefits, like fewer cases of heatstroke, we now know it can help with mental health , cognition , and … stock market returns. In 1965, Congress mandated labeling on all cigarette packaging that warned consumers about the risks of smoking.

Disease 73

Disease Vaccine Nurses Engineering 73

Drug & Device Law

JANUARY 4, 2024

2012), we hailed it as the best decision of 2012. purchase, marketing, promotion, . . development, clinical testing or investigation, distribution, purchase, marketing, promotion, sale, purchase, or use” of an immune covered countermeasure. Hamilton , 372 S.W.3d 3d 140 (Tex. Well, that’s different. 247d-6d(b)(8).

Vaccine 59

Vaccine FDA FDA Approval Production 59

Drug & Device Law

AUGUST 3, 2023

Way back in September 2012, we—in its Blog-specific veiled singular usage—did our first post. For instance, in 2012, the impacts of the decision in PLIVA, Inc. Plaintiffs did not even complain about the content of the package insert. Eleven years has also seen quite a bit of change in our space. Mensing , 564 U.S.

Doctors 52

Doctors Packaging FDA FDA Approval 52

Drug & Device Law

JULY 31, 2023

2012), computer code was not a “product” for purposes of the National Stolen Property Act, 18 U.S.C. no[r] a marketing product” under Lanham Act). 2012 WL 5932437 (N.D. 27, 2012), limited the undefined term “product” in an Alabama sales commission statute to tangible things, excluding franchise rights. at 1293-94.

Production 52

Production Trials International Government 52

Drug & Device Law

SEPTEMBER 12, 2022

The case alleged on-label drug use between 2009 and early 2012, purportedly leading to plaintiffs’ decedent’s suicide in 2013 – more than a year after use of the drug had ceased. The group requested that the FDA either withdraw marketing approval. . . citations omitted).

FDA 59

FDA FDA Approval Regulations International 59

Drug & Device Law

JUNE 6, 2022

2012), it had to apply the rule. 2012 WL 12848432, at *4 (E.D. 4, 2012) (no causation were, “[u]nderstanding the known risks,” the prescribing physicians testified that “they stand by their decisions to prescribe”), aff’d , 747 F.3d 26, 2015); In re Plavix Product & Marketing Cases , 2017 WL 2882212, at *3 (Cal.

Testimonials 59

Testimonials Production Pharmaceuticals Drugs 59

Drug & Device Law

MAY 30, 2022

2012) (no proof that hypothetical “Dear Doctor letter” or on-product warning would have causal effect given that risk had arisen only once in implanter’s several thousand similar surgeries) (applying Tennessee law); Eck v. In In re Plavix Marketing, Sales Practices & Products Liability Litigation , 2017 WL 4838842 at *6-7 (D.N.J.

Testimonials 59

Testimonials Doctors Production Laboratories 59

Drug & Device Law

MARCH 16, 2022

In Arizona, a manufacturer cannot be liable for punitive damages if the product was “designed, manufactured, packaged, labeled, sold or represented in relevant and material respects according to the terms of an approval, conditional approval, clearance, license or similar determination of a government agency.”

FDA 69

FDA Production Trials Government 69